A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
Clinical trial NCT02500927 · TERMINATED
Trial details
- NCT number
- NCT02500927
- Sponsor
- Astellas Pharma Inc
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-25
- Primary completion
- 2017-06-09
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.